TriangleNCT01835158 · CITED IN SOURCE DOCUMENTS
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2021-02-11
This randomized phase II trial studies how well cabozantinib-s-malate works compared to sunitinib malate in treating patients with previously untreated kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Cabozantinib-s-malate and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether cabozantinib-s-malate is more effective than sunitinib malate in treating patients with kidney cancer.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Renal cell carcinoma with some component of clear cell histology; histologic documentation of metastatic disease is not required * Locally advanced (defined as disease not amenable to curative surgery or radiation therapy) or metastatic renal cell carcinoma (RCC) (equivalent to stage IV RCC, according to American Joint Committee on Cancer \[AJCC\] staging) * Eligible patients must be intermediate/poor risk, per the International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium (Heng) criteria; patients must therefore have as one or more of the following six factors: * Time from diagnosis of RCC to systemic treatment \< 1 year * Note: systemic treatment refers to the initiation of A031203 protocol treatment * Hemoglobin \< the lower limit of normal (LLN) * Corrected calcium \> the upper limit of normal (ULN) * Karnofsky performance status \< 80% * Neutrophil count \> ULN * Platelet count \> ULN * No radiographic evidence of cavitating pulmonary lesion(s) * No tumor invading the inferior vena cava (IVC) or superior vena cava (SVC) blood vessels * No evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days prior to registration * No prior systemic treatment for RCC; supportive therapies such as bisphosphonates (zoledronic acid) or denosumab are permitted * Patients must not have had a major surgical procedure or significant traumatic injury within 6 weeks prior to study registration, and must have fully recovered from any such procedure; however, patients who have had a nephrectomy may be enrolled 4 weeks after surgery, providing there are no wound-healing complications; the following are not considered to be major procedures: thoracentesis, paracentesis, port placement, laparoscopy, thoracoscopy, bronchoscopy, endoscopic ultrasonographic procedures, mediastinoscopy, skin biopsies, incisional biopsies, imaging-guided biopsy for diagnostic purposes, and routine dental procedures * Radiation: * To the brain, thoracic cavity, abdomen, or pelvis must be completed at least 90 days before registration; * To bone must be completed at least 14 days before registration; and * To any other sites must be completed at least 28 days before registration In all cases, there must be complete recovery and no ongoing complications from prior radiation therapy * No chronic concomitant treatment of strong cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducers or inhibitors; patients may not have received a strong CYP3A4 inducer within 12 days prior to registration nor a strong CYP3A4 inhibitor within 7 days prior to registration * Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria; lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>= 2 cm with conventional techniques or as \>= 1 cm with spiral computed tomography (CT) scan * No active brain metastases; patients with treated, stable brain metastases for at least three months are eligible as long as they meet the following criteria: * Treated brain metastases are defined as having no ongoing requirement for steroids and no evidence of progression or hemorrhage after treatment for at least 3 months, as ascertained by clinical examination and brain imaging (magnetic resonance imaging \[MRI\] or CT); (stable dose of anticonvulsants are allowed); treatment for brain metastases may include whole brain radiotherapy (WBRT), radiosurgery (RS; Gamma Knife, linear accelerator \[LINAC\], or equivalent) or a combination as deemed appropriate by the treating physician; patients with central nervous system (CNS) metastases treated by neurosurgical resection or brain biopsy performed within 3 months prior to registration are not eligible * Baseline brain imaging (MRI/CT) is required * No serious non-healing wound, ulcer, or bone fracture requiring intervention within 28 days prior to registration * No arterial thrombotic events within 6 months prior to registration, including transient ischemic attack (TIA), cerebrovascular accident (CVA), peripheral arterial thrombus, unstable angina or angina requiring surgical or medical intervention in the 6 months prior to registration, or myocardial infarction (MI); patients with clinically significant peripheral artery disease (i.e., claudication on less than one block), significant vascular disease (i.e., aortic aneurysm, history of aortic dissection), or any other arterial thrombotic event are ineligible * No history of pulmonary embolism or untreated deep venous thrombosis (DVT) within 6 months prior to registration; note: patients with recent DVT who have been treated with therapeutic anticoagulation with low molecular weight heparin for at least 6 weeks are eligible; patients receiving therapeutic warfarin (\> 2 mg/day) are not eligible; patients on warfarin may be switched to low molecular weight heparin at the discretion of the treating physician * No inadequately controlled hypertension (defined as a blood pressure of \>= 150 mmHg systolic and/or \>= 90 mmHg diastolic), or any prior history of hypertensive crisis or hypertensive encephalopathy * No New York Heart Association (NYHA) class \>= 2 congestive heart failure * Ejection fraction on echocardiogram (Echo) or multi gated acquisition scan (MUGA) \> 50% * No corrected QT interval calculated by the Fridericia formula (QTcF) \> 500 ms within 28 days before randomization; note: if initial QTcF is found to be \> 500 ms, two additional electrocardiograms (EKGs) separated by at least 3 minutes should be performed; if the average of these three consecutive results for QTcF is =\< 500 ms, the subject meets eligibility in this regard * No history of congenital QT syndrome * No unstable cardiac arrhythmia within 6 months prior to registration * No evidence of any of the following: * Clinically-significant gastrointestinal bleeding within 6 months before registration; or * Hemoptysis of \>= 0.5 teaspoon (2.5 mL) of red blood within 3 months before registration; or * Any other signs indicative of pulmonary hemorrhage within 3 months before registration * No history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, bowel obstruction, or gastric outlet obstruction within 6 months prior to registration and complete healing/resolution prior to registration; no percutaneous endoscopic gastrostomy (PEG) tube placement within 3 months prior to registration * No active peptic ulcer disease, within 28 days before registration * No inflammatory bowel disease (including ulcerative colitis and Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis within 28 days before registration * No malabsorption syndrome within 28 days before registration * No uncompensated hypothyroidism; patients with hypothyroidism on therapy are required to have thyroid stimulating hormone (TSH) within normal limits * No radiologic or clinical evidence of pancreatitis * No history of organ transplant * Patients with active infection requiring systemic treatment within 28 days prior to registration are not eligible * Patients who are pregnant or nursing are not eligible; women of child bearing potential must have a negative serum or urine pregnancy test within 16 days prior to registration; women of child-bearing potential include: * Any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea \>= 12 consecutive months) * Women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level \> 35m IU/mL * Women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy) * Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2 * Archival tissue must be available for submission, though it is optional for patients to choose to participate in the correlative sub studies * Absolute neutrophil count (ANC) \>= 1,500/uL * Platelet count \>= 100,000/uL * Hemoglobin \>= 9 g/dL; patients may not have had a transfusion within 7 days prior to screening assessment * Total bilirubin =\< 1.5 x upper limits of normal * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 2.5 x ULN * Albumin \>= 2.8 g/dL * Serum creatinine =\< 1.5 x ULN, OR calculated creatinine clearance \>= 30 mL/minute (modified Cockcroft and Gault formula) * Urine protein to creatinine (UPC) ratio \< 1.0; if UPC \>= 1, then a 24-hour urine protein must be assessed; eligible patients must have a 24-hour urine protein value \< 1 g * Total serum calcium \< 12 mg/dL * International normalized ratio (INR) =\< 1.2 x ULN; subjects receiving anticoagulant therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulation * TSH within normal limits (WNL); TSH only required for patients on thyroid supplementation
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Patients receive cabozantinib-s-malate PO QD for 6 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
- intervention Names
- Drug: Cabozantinib S-malate
- Other: Laboratory Biomarker Analysis
- label
- Arm I (cabozantinib-s-malate)
- type
- ACTIVE_COMPARATOR
- description
- Patients receive sunitinib malate PO QD for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
- intervention Names
- Other: Laboratory Biomarker Analysis
- Drug: Sunitinib Malate
- label
- Arm II (sunitinib malate)
- type
- ACTIVE_COMPARATOR
- interventions
- arm Group Labels
- Arm I (cabozantinib-s-malate)
- description
- Given PO
- name
- Cabozantinib S-malate
- other Names
- BMS-907351
- Cabometyx
- Cometriq
- XL-184
- XL184
- type
- DRUG
- arm Group Labels
- Arm I (cabozantinib-s-malate)
- Arm II (sunitinib malate)
- description
- Correlative studies
- name
- Laboratory Biomarker Analysis
- type
- OTHER
- arm Group Labels
- Arm II (sunitinib malate)
- description
- Given PO
- name
- Sunitinib Malate
- other Names
- SU011248
- SU11248
- sunitinib
- Sutent
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 157
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Progression free survival (PFS) was investigator assessed and is measured from the beginning of treatment until patient progression or death. Progression was determined using RECIST 1.1 criteria, progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).The primary analysis will be based on the stratified log-rank statistic to compare the two treatment arms on PFS. The Kaplan-Meier product-limit estimator will be used to estimate PFS distributions.Progression Free Survival was assessed per investigator, as this was the protocol-specified endpoint, and both investigator and independent review analyses of the PFS endpoint have been published
- measure
- Progression Free Survival (PFS)
- time Frame
- Up to 5 years
- description
- The primary analysis will be based on the stratified log-rank statistic to compare the two treatment arms on OS. The Kaplan-Meier product-limit estimator will be used to estimate OS distributions.
- measure
- Overall Survival (OS)
- time Frame
- Up to 5 years
- secondary Outcomes
- description
- Objective response rates (ORR) was investigator assessed. ORR is the rate of complete or partial responses, based on RECIST 1.1 criteria. A response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. The Fisher exact test will be used to compare the two treatment arms.
- measure
- Objective Response Rates
- time Frame
- Up to 5 years
Full study description
- brief Summary
- This randomized phase II trial studies how well cabozantinib-s-malate works compared to sunitinib malate in treating patients with previously untreated kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Cabozantinib-s-malate and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether cabozantinib-s-malate is more effective than sunitinib malate in treating patients with kidney cancer.
- detailed Description
- PRIMARY OBJECTIVES: I. To determine if patients with renal cancer treated with cabozantinib (cabozantinib-s-malate) will have improved progression-free survival compared to patients treated with sunitinib (sunitinib malate). SECONDARY OBJECTIVES: I. To determine whether the response rate of patients with renal cancer treated with cabozantinib will be higher when compared with patients treated with sunitinib. II. To determine whether patients with renal cancer treated with cabozantinib will have an improved overall survival when compared with patients treated with sunitinib. TERTIARY OBJECTIVES: I. To determine whether renal cancer patients with high MET expression by immunohistochemistry (IHC) have improvement in progression-free survival compared to patients with low MET expression on both arms of this study. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive cabozantinib-s-malate orally (PO) once daily (QD) for 6 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive sunitinib malate PO QD for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6 months for 5 years.
Source references
- references
- citation
- Aldin A, Besiroglu B, Adams A, Monsef I, Piechotta V, Tomlinson E, Hornbach C, Dressen N, Goldkuhle M, Maisch P, Dahm P, Heidenreich A, Skoetz N. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023 May 4;5(5):CD013798. doi: 10.1002/14651858.CD013798.pub2.
- pmid
- 37146227
- type
- DERIVED
- citation
- George DJ, Hessel C, Halabi S, Michaelson MD, Hahn O, Walsh M, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, Morris MJ, Choueiri TK. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. Oncologist. 2019 Nov;24(11):1497-1501. doi: 10.1634/theoncologist.2019-0316. Epub 2019 Aug 9.
- pmid
- 31399500
- type
- DERIVED
- citation
- Flaifel A, Xie W, Braun DA, Ficial M, Bakouny Z, Nassar AH, Jennings RB, Escudier B, George DJ, Motzer RJ, Morris MJ, Powles T, Wang E, Huang Y, Freeman GJ, Choueiri TK, Signoretti S. PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. Clin Cancer Res. 2019 Oct 15;25(20):6080-6088. doi: 10.1158/1078-0432.CCR-19-1135. Epub 2019 Aug 1.
- pmid
- 31371341
- type
- DERIVED
- citation
- Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018 May;94:115-125. doi: 10.1016/j.ejca.2018.02.012. Epub 2018 Mar 20.
- pmid
- 29550566
- type
- DERIVED
- citation
- Choueiri TK, Halabi S, Morris MJ, George D. Reply to B. Rini et al and S. Buti et al. J Clin Oncol. 2017 Jun 1;35(16):1859-1860. doi: 10.1200/JCO.2017.72.2629. Epub 2017 Mar 6. No abstract available.
- pmid
- 28549224
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-b7d197fadf7853eabf81
- requested nct id
- NCT01835158
- primary nct id
- NCT01835158
- source kind
- fda_spl_label
- source record id
- e8cdcbdc-d863-4d48-af3e-a8926b9ab017
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- payload sha256
- 84aafc4b7e2b4b8cdd18238eab0c91eb77f798ecadb84d3639c905f8b535aae0
- payload
- application numbers
- NDA208692
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-b7d197fadf7853eabf81
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01835158
- occurrences
- context exact
- test p<0.0001 Figure 2: Kaplan-Meier Curve of Overall Survival in METEOR (ITT) First-line Treatment CABOSUN The efficacy of CABOMETYX was evaluated in CABOSUN (NCT01835158), a randomized (1:1), open-label, multicenter trial of CABOMETYX versus sunitinib conducted in patients with advanced RCC who had not received prior therapy. P
- end
- 3125
- exact text
- NCT01835158
- start
- 3114
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00700.json
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source json pointer
- /results/76/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- e8cdcbdc-d863-4d48-af3e-a8926b9ab017
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 082cf58b7d3c278fdf2e8054fd1bd83caca3ee15d62ed95bae138c2fbee6f3c7
- spl effective time
- 20251019
- spl set id
- 3850cce2-6137-42e5-a792-d318c4a4b3b5
Preserved source evidence · Not medical advice